Man Group
CLDX icon

Man Group’s Celldex Therapeutics CLDX Stock Holding History

Man Group’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.36M Buy
+63,504
New +$2.05M ﹤0.01% 1492
2024
Q4 		– Sell
-35,967
Closed -$1.22M – 2009
2024
Q3 		$1.22M Buy
+35,967
New +$1.37M ﹤0.01% 1452
2018
Q4 		– Sell
-733
Closed -$5K – 1939
2018
Q3 		$5K Hold
733
– – ﹤0.01% 2064
2018
Q2 		$6K Sell
733
-26,960
-97% -$360K ﹤0.01% 2089
2018
Q1 		$968K Buy
+27,693
New +$1.07M ﹤0.01% 1533

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Man Group's CLDX Position: Q2 2026 in Review

Man Group opened a new position in Celldex Therapeutics (CLDX) in Q2 2026: 63,504 shares worth $2.36M. The stake represents ﹤0.01% of the portfolio and ranks #1492 among its holdings. This is a return to the name: Man Group previously reported a position in CLDX as recently as Q3 2024.

Man Group first reported a position in CLDX in Q1 2018 and has held it in 5 quarters since. 254 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Man Group held 63,504 shares of Celldex Therapeutics worth $2.36M as of Q2 2026.
  • Celldex Therapeutics was a new Man Group position in Q2 2026.
  • Celldex Therapeutics made up ﹤0.01% of Man Group's portfolio in Q2 2026, its #1492 holding.
  • Man Group first reported a position in Celldex Therapeutics in Q1 2018 and has held it in 5 quarters since.
  • 254 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.